Abstract：
Squamous cell carcinomas of the head and neck (SCCHN) account for approximately 4% of all malignancies and are associated with high morbidity and poor prognosis. For patients who are not eligible for surgery or radiotherapy, treatment options are limited, especially for those with recurrent or metastatic (R/M) disease. Current European guidelines recommend first-line (1L) treatment with palliative chemotherapy, using biologic or platinum-based regimens. In the absence of new clinical trials in SCCHN, the use of real-world data has facilitated the assessment of treatment patterns and outcomes in different healthcare systems. This study reports on the 1L treatment of platinum-eligible patients with R/M SCCHN in Italy and Spain.
A point-in-time survey of the management of patients with R/M SCCHN was completed by clinical oncologists in Italy and Spain between October 2018 and February 2019. Patient demographics and clinical characteristics were obtained by retrospective chart review, whilst participating patients self-reported the impact of their disease on their quality of life (QoL) and well-being.
A total of 436 patients were recruited from Italy (216) and Spain (220). Patient demographics for both countries comprised mostly male patients, aged 65 years in Italy and 63 in Spain on average. The primary site for the SCCHN was the pharynx and 36% of patients had metastatic disease overall. EXTREME or cetuximab-based regimens were the most common treatments administered at 1L (52% in Italy and 78% in Spain). Scores on the FACT-G in both countries were substantially lower than those of the general and other advanced cancer populations, while scores on the EQ-5D were clinically meaningfully lower than local population norms.
Despite 1L treatment of platinum-eligible patients with R/M SCCHN in Italy and Spain following current European guidelines, patients\' QoL remains poor, which highlights the need for alternative treatments that could improve clinical outcomes.
A point-in-time survey of the management of patients with R/M SCCHN was completed by clinical oncologists in Italy and Spain between October 2018 and February 2019. Patient demographics and clinical characteristics were obtained by retrospective chart review, whilst participating patients self-reported the impact of their disease on their quality of life (QoL) and well-being.
A total of 436 patients were recruited from Italy (216) and Spain (220). Patient demographics for both countries comprised mostly male patients, aged 65 years in Italy and 63 in Spain on average. The primary site for the SCCHN was the pharynx and 36% of patients had metastatic disease overall. EXTREME or cetuximab-based regimens were the most common treatments administered at 1L (52% in Italy and 78% in Spain). Scores on the FACT-G in both countries were substantially lower than those of the general and other advanced cancer populations, while scores on the EQ-5D were clinically meaningfully lower than local population norms.
Despite 1L treatment of platinum-eligible patients with R/M SCCHN in Italy and Spain following current European guidelines, patients\' QoL remains poor, which highlights the need for alternative treatments that could improve clinical outcomes.
摘要：
头颈部鳞状细胞癌（SCCHN）约占所有恶性肿瘤的4％，并与高发病率和不良预后相关。对于不符合手术或放疗条件的患者，治疗选择有限，特别是对于那些复发或转移性（R/M）疾病。目前的欧洲指南推荐一线（1L）治疗姑息化疗，使用生物或铂类药物治疗方案。在SCCHN没有新的临床试验的情况下，现实世界数据的使用促进了对不同医疗保健系统中治疗模式和结果的评估.本研究报道了意大利和西班牙的R/MSCCHN对铂类患者的1L治疗。
2018年10月至2019年2月，意大利和西班牙的临床肿瘤学家完成了对R/MSCCHN患者管理的时间点调查。通过回顾性图表回顾获得患者的人口统计学和临床特征，而参与患者自我报告其疾病对其生活质量（QoL）和幸福感的影响。
总共从意大利（216）和西班牙（220）招募了436名患者。这两个国家的患者人口统计数据主要包括男性患者，意大利平均65岁，西班牙平均63岁。SCCHN的主要部位是咽部，总体上有36％的患者患有转移性疾病。以EXTREME或西妥昔单抗为基础的方案是最常见的1L治疗（意大利52%，西班牙78%）。这两个国家的FACT-G得分远低于普通和其他晚期癌症人群，而EQ-5D的评分在临床上有意义地低于当地人群标准。
尽管按照目前的欧洲指南，意大利和西班牙的R/MSCCHN对符合铂类标准的患者进行了1L治疗，患者的QoL仍然很差，这凸显了对可以改善临床结果的替代疗法的需求。
2018年10月至2019年2月，意大利和西班牙的临床肿瘤学家完成了对R/MSCCHN患者管理的时间点调查。通过回顾性图表回顾获得患者的人口统计学和临床特征，而参与患者自我报告其疾病对其生活质量（QoL）和幸福感的影响。
总共从意大利（216）和西班牙（220）招募了436名患者。这两个国家的患者人口统计数据主要包括男性患者，意大利平均65岁，西班牙平均63岁。SCCHN的主要部位是咽部，总体上有36％的患者患有转移性疾病。以EXTREME或西妥昔单抗为基础的方案是最常见的1L治疗（意大利52%，西班牙78%）。这两个国家的FACT-G得分远低于普通和其他晚期癌症人群，而EQ-5D的评分在临床上有意义地低于当地人群标准。
尽管按照目前的欧洲指南，意大利和西班牙的R/MSCCHN对符合铂类标准的患者进行了1L治疗，患者的QoL仍然很差，这凸显了对可以改善临床结果的替代疗法的需求。
